What are people willing to pay for whole genome sequencing information?

Abstract

Whole genome sequencing (WGS) can be used to predict future disease risk or inform treatment. Current guidelines suggest only reporting variants that are clinically actionable. Reporting incidental or non-actionable findings could generate anxiety and unnecessary medical tests, but patients could miss valuable information if not reported. Over-treatment may occur by acting on findings prematurely, potentially causing harm and unnecessary resource use. We measure the value of WGS information using contingent valuation methods.